A team led by Michael Laflamme, a clinician-scientist at the McEwen Stem Cell Institute at UHN, is developing a novel injectable cell therapy to repair hearts damaged by heart attack or disease. Made from stem cells, the therapy targets scar tissue, back into muscle. Eventually, this therapy could replace the need for a heart transplant. Read more.
Medicine by Design’s Michael Sefton, scientific director, and University Health Network’s Bradly Wouters, executive VP, science and research, publish an op-ed in the Toronto Star.
New program to offer broad training in regenerative medicine including the integration of Medicine by Design's entrepreneurship and commercialization programs.
"I truly believe we’re on the brink of understanding our science in a way that will enable us to really move forward and help people living with type 1 diabetes."
Transformative research highlighted as part of Heart Month
Event was part of a series that explores convergent approaches in Medicine by Design’s team projects
New initiative to include social scientists, policy experts, industry leaders, patients and others
Research trainees from around the world are encouraged to apply by Jan. 23, 2023
Field leaders come together to explore the "Grand Questions in Regenerative Medicine."
On Dec. 8, the Medicine by Design symposium will explore some of regenerative medicine's most important and challenging questions
"We’re trying to understand the biology behind diseases and target the abnormal behavior that actually happens inside the cells."
Professor Omar F. Khan’s lab group is designing new platforms that deliver RNA to the body, addressing a range of biomedical challenges
Partnership to accelerate health innovation commercialization in the Toronto life sciences ecosystem and in Canada
Polymer and tissue regeneration expert discussed her multi-pronged approach to seeking treatments for eye diseases
Medicine by Design’s Scientific Director, Michael Sefton, publishes an op-ed in the Hill Times.
